Computer model reveals cancer's energy source

August 1, 2014 by Krishna Ramanujan
Whole-body PET scan using radioactive glucose to show liver metastases of a colorectal tumor. Doctors inject patients with radioactive glucose and then watch where it is consumed; tumors are a major source of consumption. Credit: Jens Maus

(Medical Xpress)—A computer model study reveals – for the first time – details of an energy-creating process vital and unique to cancer cells. The research holds promise for new interventions and for personalizing cancer treatments based on individual needs.

The findings, which will revise basic biochemistry textbooks, focused on the energy-making process in cancer cells known as the Warburg Effect.

The Cornell-led study, published July 9 in the journal eLife, revealed that some of the enzymes thought to have no effect on the Warburg Effect, in fact, play a large role: An enzyme called GAPDH influences many parts of a cancer cell's energy-making pathway.

"Our findings open opportunities for new ways to intervene in the Warburg Effect," said Jason Locasale, the paper's senior author and assistant professor of nutritional sciences in Cornell's College of Agricultural and Life Sciences. Alexander Shestov, a former senior research associate, and Xiaojing Liu, a postdoctoral fellow, both in Locasale's lab, are the paper's lead authors. The results also "provide glimpses into whether we have predictive capacity to discern if treatments might be working," Locasale added.

All multicellular organisms evolved pathways that take nutrients, sugars and oxygen and make energy through respiration and chemical processes. In , this energy-making process is known as . But when cells evolve cancerous properties and grow uncontrollably, they instead ferment their sugars to create energy even in the presence of oxygen. This process is called aerobic glycolysis, or the Warburg Effect.

The new findings are an important step toward developing a drug that affects only fermentation and not the normal metabolism of glucose, thereby depriving of energy. The new model lays groundwork for predicting whether treatments will be effective based on an individual's unique metabolism.

Still, very few details have been known about the Warburg Effect. "We can now systematically perturb anything in the [computer] model and identify important components" of the Warburg Effect, Locasale said.

Dating back to work by Efraim Racker, a Cornell researcher who made seminal discoveries in the area in the 1970s, followed by advances in cancer and genetic research, it is "known now that almost every cancer gene has some capacity to induce the Warburg Effect," making it fundamental to proliferative diseases, Locasale said.

Currently, the Warburg Effect is used in clinical practice to diagnose and monitor cancer. Doctors inject patients with radioactive glucose and then watch where it is consumed; tumors are a major source of consumption. Researchers are also exploring whether dietary interventions with less sugar and the use of diabetes drugs that lower glucose may impact the Warburg Effect to treat cancer.

Explore further: Discovery of a mechanism that makes tumor cells sugar addicted

Related Stories

Discovery of a mechanism that makes tumor cells sugar addicted

April 4, 2014
For almost a hundred years ago is known that cancer cells feel a special appetite for a type of sugar called glucose. The tumor uses this molecule is like the gasoline which depends a sports car to burn faster and grows and ...

Lactate metabolism target halts growth in lung cancer model

April 10, 2014
Cancer cells generate energy differently than normal cells, a characteristic that helps them to survive and metastasize. A major goal in the field of cancer metabolism is to find ways to overcome this survival advantage.

Targeting cancer's sweet tooth

October 21, 2013
Ludwig researchers have elucidated a key mechanism by which cancer cells change how they metabolize glucose to generate the energy and raw materials required to sustain runaway growth.

Study reveals new molecular target for melanoma treatment

August 17, 2012
A laboratory study led by UNC medical oncologist Stergios Moschos, MD, demonstrates how a new targeted drug, Elesclomol, blocks oxidative phosphorylation, which appears to play essential role in melanoma that has not been ...

Link between colon cancer and metabolism identified

May 13, 2014
More than 60 years ago Otto Warburg recognized that cancer cells differ from normal cells in the metabolic pathway they use for the oxidation of sugar. Rather than the typical series of oxidative steps that take place in ...

Mdm2 suppresses tumors by pulling the plug on glycolysis

February 24, 2014
Cancer cells have long been known to have higher rates of the energy-generating metabolic pathway known as glycolysis. This enhanced glycolysis, a phenomenon known as the Warburg effect, is thought to allow cancer cells to ...

Recommended for you

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.